ClinicalTrials.gg
CompletedNCT00635609Updated Apr 20, 2012Results posted

Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate

A Phase 4 interventional study of Doxycycline hyclate (Doryx) and Doxycycline hyclate in Acne Vulgaris, sponsored by Warner Chilcott. Completed at 4 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2012-04-20.

Sponsored by Warner Chilcott (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing doxycycline in Acne Vulgaris — 2 open to participants now, 3 under way, none of them phase 3. Doxycycline · Acne Vulgaris.

Enrollment
5th of 12
93 · median 47
Started
2008
with 1 other
Phase 4
6 of 12
1 open now
Registered
3rd of 12
by date
Lead sponsor
2 of 12
Warner Chilcott

Among the 12 studies testing doxycycline in Acne Vulgaris, this one is the 5th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 4, and was the 3rd registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

2 of the 12 studies testing doxycycline in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About doxycycline

Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing doxycycline in Acne Vulgaris, or all of them as a file.
02

Study summary

Randomized, multi-center, open label, active-comparator study to compare the efficacy and tolerability of Doryx Delayed Release Tablets to doxycycline hyclate in patients with moderate to severe acne vulgaris.

Read the detailed description

Efficacy of Doryx Delayed Release Tablets to doxycycline hyclate will be assessed using an Investigator's Global Assessment (IGA) score and the absolute change from baseline to 12 weeks in inflammatory lesion count in patients with moderate to severe facial acne vulgaris. Additionally, the absolute change from baseline to 12 weeks in non-inflammatory lesions count of Doryx Delayed Release Tablets compared to doxycycline hyclate will be evaluated.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be 12 years of age or older.
  • Has a diagnosis of facial acne vulgaris with no more than two nodules on the face.

Exclusion criteria

Exclusion Criteria:

  • Is allergic to tetracycline-class antibiotics or to any ingredient in the study medication.
  • Has a history of pseudomembranous colitis or antibiotic-associated colitis.
  • Has a history of hepatitis or liver damage or renal impairment.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Doxycycline hyclate (Doryx)

    Drug: Doxycycline hyclate (Doryx)

  • Active comparator
    Doxycycline hyclate

    Drug: Doxycycline hyclate

Interventions

06

What researchers measure

Primary outcomes

  1. Successful Outcome According to Investigator's Global Assessment (IGA)

    The Investigator's Global Assessment (IGA) was performed at baseline and at 12 weeks. The IGA score is based on a 5-point acne severity scale from zero (clear) to 4 (severe). Successful outcome is at least a 2-point reduction in IGA score from baseline to 12 weeks.

    Time frame: baseline and 12 weeks

  2. Change From Baseline in Inflammatory Acne Lesion Count on the Face at 12 Weeks

    Acne lesions fall into 2 groups: inflammatory and non-inflammatory. The number of inflammatory acne lesions on the face was measured at baseline and after 12 weeks. The difference (change) was calculated.

    Time frame: baseline and 12 weeks

Secondary outcomes

  1. Change From Baseline in Non-inflammatory Acne Lesion Count on the Face at 12 Weeks

    Acne lesions fall into 2 groups: inflammatory and non-inflammatory. The number of non-inflammatory acne lesions on the face was measured at baseline and after 12 weeks. The difference (change) was calculated.

    Time frame: baseline and 12 weeks

07

Results

Posted Dec 30, 2009

Participant flow

Participant flow — Overall Study
MilestoneDoxycycline Hyclate (Doryx) Delayed-release TabletsDoxycycline Hyclate Immediate-release Tablets
Started4845
Completed4142
Not completed73

Outcome measures

PrimarySuccessful Outcome According to Investigator's Global Assessment (IGA)

The Investigator's Global Assessment (IGA) was performed at baseline and at 12 weeks. The IGA score is based on a 5-point acne severity scale from zero (clear) to 4 (severe). Successful outcome is at least a 2-point reduction in IGA score from baseline to 12 weeks.

Time frame:
baseline and 12 weeks
Reported as:
Number · participants
Successful Outcome According to Investigator's Global Assessment (IGA)
participantsDoxycycline Hyclate (Doryx) Delayed-release TabletsDoxycycline Hyclate Immediate-release Tablets
Successful Outcome According to Investigator's Global Assessment (IGA)1819
Statistical analysis
  • Doxycycline Hyclate (Doryx) Delayed-release Tablets vs Doxycycline Hyclate Immediate-release Tablets · Cochran-Mantel-Haenszel · p = 0.765Stratified on investigational site.
SecondaryChange From Baseline in Non-inflammatory Acne Lesion Count on the Face at 12 Weeks

Acne lesions fall into 2 groups: inflammatory and non-inflammatory. The number of non-inflammatory acne lesions on the face was measured at baseline and after 12 weeks. The difference (change) was calculated.

Time frame:
baseline and 12 weeks
Reported as:
Mean · Acne lesion count
Change From Baseline in Non-inflammatory Acne Lesion Count on the Face at 12 Weeks
Acne lesion countDoxycycline Hyclate (Doryx) Delayed-release TabletsDoxycycline Hyclate Immediate-release Tablets
Change From Baseline in Non-inflammatory Acne Lesion Count on the Face at 12 Weeks23.2 ± 19.327.6 ± 20.0
Statistical analysis
  • Doxycycline Hyclate (Doryx) Delayed-release Tablets vs Doxycycline Hyclate Immediate-release Tablets · Cochran-Mantel-Haenszel · p = 0.290Stratified on investigational site.
PrimaryChange From Baseline in Inflammatory Acne Lesion Count on the Face at 12 Weeks

Acne lesions fall into 2 groups: inflammatory and non-inflammatory. The number of inflammatory acne lesions on the face was measured at baseline and after 12 weeks. The difference (change) was calculated.

Time frame:
baseline and 12 weeks
Reported as:
Mean · acne lesion count
Change From Baseline in Inflammatory Acne Lesion Count on the Face at 12 Weeks
acne lesion countDoxycycline Hyclate (Doryx) Delayed-release TabletsDoxycycline Hyclate Immediate-release Tablets
Change From Baseline in Inflammatory Acne Lesion Count on the Face at 12 Weeks21.8 ± 13.826.6 ± 12.5
Statistical analysis
  • Doxycycline Hyclate (Doryx) Delayed-release Tablets vs Doxycycline Hyclate Immediate-release Tablets · Cochran-Mantel-Haenszel · p = 0.033Stratified on investigational site

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Doxycycline Hyclate (Doryx) Delayed-release Tablets—1/48 (2.1%)10/48 (20.8%)
Doxycycline Hyclate Immediate-release Tablets—1/45 (2.2%)11/45 (24.4%)
Most frequent serious events
Most frequent serious events
EventDoxycycline Hyclate (Doryx) Delayed-release TabletsDoxycycline Hyclate Immediate-release Tablets
Ruptured ectopic pregnancyPregnancy, puerperium and perinatal conditions0/481/45
Acute cholecystitisHepatobiliary disorders1/480/45
Most frequent other events
Most frequent other events
EventDoxycycline Hyclate (Doryx) Delayed-release TabletsDoxycycline Hyclate Immediate-release Tablets
HeadacheNervous system disorders7/483/45
NauseaGastrointestinal disorders0/484/45
NasopharyngitisRespiratory, thoracic and mediastinal disorders0/483/45
SunburnInjury, poisoning and procedural complications3/481/45

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Doxycycline Hyclate (Doryx) Delayed-release TabletsDoxycycline Hyclate Immediate-release TabletsTotal
<=18 years282149
Between 18 and 65 years202444
>=65 years000
Age Continuous
Age Continuous(years)Doxycycline Hyclate (Doryx) Delayed-release TabletsDoxycycline Hyclate Immediate-release TabletsTotal
Mean19.3 ± 5.820.9 ± 7.920.1 ± 6.9
Sex: Female, Male
Sex: Female, Male(Participants)Doxycycline Hyclate (Doryx) Delayed-release TabletsDoxycycline Hyclate Immediate-release TabletsTotal
Female171633
Male312960
Region of Enrollment
Region of Enrollment(participants)Doxycycline Hyclate (Doryx) Delayed-release TabletsDoxycycline Hyclate Immediate-release TabletsTotal
United States484593
Ethnic Origin
Ethnic Origin(participants)Doxycycline Hyclate (Doryx) Delayed-release TabletsDoxycycline Hyclate Immediate-release TabletsTotal
Hispanic272653
Not of Hispanic origin211940
Race
Race(participants)Doxycycline Hyclate (Doryx) Delayed-release TabletsDoxycycline Hyclate Immediate-release TabletsTotal
Asian or Pacific Islander011
Black358
Caucasian221840
Other232144
08

Study locations

4 sites
  • Warner Chilcott Investigational Site
    Vista, California 92083, United States
  • Warner Chilcott Investigational Site
    Miami, Florida 33175, United States
  • Warner Chilcott Investigational Site
    Louisville, Kentucky 40217, United States
  • Warner Chilcott Investigational Site
    Rochester, New York 14623, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2008
First posted
Mar 14, 2008
Start
Mar 2008
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Dec 30, 2009
Last update
Apr 20, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00635609
Lead sponsor
Warner Chilcott
Responsible party
Sponsor
First posted
Mar 14, 2008
Start date
Mar 2008
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Dec 30, 2009
Last update
Apr 20, 2012

Study contacts

Angelo Secci, MD
study director · Warner Chilcott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxycycline

Start the discussion